Faes Farma SA
MAD:FAE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (18.5), the stock would be worth €2.77 (42% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 31.8 | €4.76 |
0%
|
| 3-Year Average | 18.5 | €2.77 |
-42%
|
| 5-Year Average | 21.5 | €3.22 |
-32%
|
| Industry Average | 34.1 | €5.11 |
+7%
|
| Country Average | 18.6 | €2.78 |
-42%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
F
|
Faes Farma SA
MAD:FAE
|
1.5B EUR | 31.8 | 18.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 34.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 19 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 42.2 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13 |
| Median | 18.6 |
| 70th Percentile | 28.2 |
| Max | 1 712.4 |
Other Multiples
Faes Farma SA
Glance View
Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.